“I'm a coward when it comes to matters of the heart. That is my fatal flaw.” - Haruki Murakami Haruki Murakami, born in Japan in 1949, is a celebrated novelist known for blending everyday life with dreamlike and surreal elements. His writing often explores loneliness, memory, love, identity, loss, and the search for meaning. Through his distinctive storytelling style, Murakami has become an influential figure in contemporary literature, with his works translated and widely read throughout the world. The quote reflects the vulnerability and fear that can come with truly loving someone. Murakami suggests that a person may be courageous in many areas of life yet struggle when emotions become deeply personal. Loving someone means opening yourself to rejection, heartbreak, and loss, and that vulnerability can make it difficult to express what you genuinely feel. By describing this fear as a “fatal flaw,” he suggests that it is more than a minor weakness. Fear can prevent someone from saying what is in their heart or pursuing the relationship they truly want. The quote captures a deeply human contradiction: sometimes the person we care about most is also the person we are most afraid to be vulnerable with, because their ability to hurt us matters more than anyone else’s.

I'm a cardiologist, and here is the case for AI concierge medicine. It starts with an essay everyone in American healthcare should read this week: "Want Concierge Medicine? AI Can Deliver It," by Tom Rosenblatt in @WSJopinion. He's the founder of the health-longevity company Being and sits on a federal advisory panel on tech-enabled care — and he named the problem I've watched break good doctors for 25 years. h/t Eric Topol. The case, point by point. Attentive care has quietly become a luxury. When Rosenblatt went looking for a primary-care doctor in New York, the physicians with open calendars had turned to concierge practices — $12,000 a year at one, $24,000 at another. That is the going rate now for what used to just be called having a doctor: someone who knows you, sees you promptly, and has time to think about your results. More than 100 million Americans don't have that at all. This isn't a villain story. It's broken math. Primary care pays less than almost any specialty. Most medical students graduate owing over $200,000. So fewer choose the field, urgent care mops up the crises, and no one is paid to prevent anything. Here's the number that should end the debate: to deliver all the recommended preventive care for a normal patient roster, a primary-care doctor would need more than 14 hours a day. Every day. It's not that we're failing at prevention. It's mathematically impossible as built. And the country is paying for it in bodies. Only 7% of American adults have healthy blood pressure, blood sugar, cholesterol, and weight — all four. The other 93% are sitting on a slow slope from early risk to real disease. And the cruel irony is we know what pulls people back: move most days, eat mostly unprocessed food, sleep enough, stay connected. For early prediabetes and mild hypertension, those four habits can rival a prescription. But no one has 20 unhurried minutes to tailor that advice to you anymore. AI changes the arithmetic — because it doesn't get tired at hour 14. A well-built system can read years of your labs, imaging, and wearable data in seconds and catch the upward drift in five numbers at once, long before any single one crosses a red line. The heart attack that shows up at 55 was often visible in the data at 40. We simply never had eyes patient enough to watch continuously. One in three American adults already asked an AI for health advice last year. But I'm a physician, so I'll say the hard part out loud. On real clinical cases, some AI models have given safer advice than generalist doctors. And other models made a serious mistake in more than 1 in 5 cases. Right now most health AI dodges federal review entirely by calling itself a "wellness product." That gap — between the good models and the dangerous ones — is the whole ballgame. A tool this powerful cannot be sold on trust alone. Which is why the case isn't "download an app." It's build the guardrails. Rosenblatt lays out three, and as a doctor I'd sign my name to all three. Records that follow the patient automatically, so you own your full history and decide who sees it — human or AI. A public crash test for medical AI: rotating real clinical cases, scored and published, the way we rate cars for safety, so you know which system to trust with your life. And payment for outcomes instead of visits — Medicare's new ACCESS model went live July 5th, paying only when your blood pressure actually drops and your A1c actually comes down. That's the missing piece that turns an AI's warning into care someone is finally paid to deliver. Put it together and here is the whole case in one line: A doctor's time is scarce and expensive. An AI's time is nearly free. The continuous, prevention-first, always-watching attention that today costs the price of a luxury car could become available to anyone holding a phone. This is not AI replacing your physician. I have spent my life at the bedside; nothing replaces the human hand on a frightened chest. This is AI giving every person the second set of eyes and the personal foresight that, until now, only the wealthy could buy. The technology is in our pockets. The data can be made portable. The accuracy can be proven and publicly scored. The incentives are starting to change. The pieces exist. So the future of medicine gets to stop being a privilege. It becomes a right. That's the case. And it's the reason I'm building what I'm building — because I don't want to be brilliant at the worst moment of your life. I want to make sure that moment never comes. Thoughts? @rabois

I'm a cardiologist. For 25 years I've been trained to be brilliant at the worst moment of your life. The 3am cath lab. The stent threaded into a closing artery. The bypass. The shock that restarts a heart that had already quit. I've stood in those rooms more times than I can count, and I will never stop being in awe of what we can do there. But I need to tell you the quiet secret of my entire field: By the time you meet me in that room, the disease has already won most of the war. We are firefighters who show up after the house is halfway gone. We've built the most sophisticated rescue system in the history of medicine — and aimed almost none of it at stopping the fire from starting. 800,000 Americans still have a heart attack every year. A staggering share of them were preventable — not weeks earlier, but years earlier. We just had no way to see it coming. That is now changing, and the shift is so profound that ACC President @Drroxmehran and @EricTopol just laid it out as a once-in-a-generation turning point for medicine — a call to move cardiology from reacting to disease to predicting and preventing it before it ever declares itself. Here is what almost no one outside my field understands yet. Point by point. We've been staring at the wrong thing for decades. Old cardiology was obsessed with the narrowing — how clogged is the pipe on the angiogram. But here's the twist that still surprises even doctors: most heart attacks don't come from the tight, obvious blockage. They come from softer, "invisible" plaque that isn't blocking much of anything — until the day it ruptures without warning. We were reading the visible enemy and missing the one that actually kills. The real villains are inflamed, unstable plaque and the fire smoldering in the artery wall. We can now see that hidden fire. AI-powered CT scans of the heart can detect the dangerous features older imaging missed — the composition of a plaque, and the inflammation glowing in the fat around the vessel, years before anything ruptures. We are no longer guessing which plaque is a ticking clock. We're starting to read the clock directly. Your DNA can flag the danger before you have a single symptom. Polygenic risk scores add up thousands of tiny genetic variants into one number. They can identify people carrying 2 to 7 times the lifetime risk — people with normal cholesterol, no family history, no warning signs at all. A young, "healthy" 30-year-old could be walking around with a hidden inheritance we can finally catch and act on decades early. A photograph of your eye can predict your heart. This is the one that stops people cold. Deep-learning models can look at an ordinary retinal photo — the kind snapped at the optometrist — and estimate your biological age and your future heart-attack risk. The back of your eye is the only place in the entire body where we can see living blood vessels with the naked eye. It turns out they've been narrating your cardiovascular story the whole time, and we finally learned to read the language. And now the machines that tie it all together. Multimodal AI can fuse your genetics, your imaging, your medical record, and the data streaming off your watch into a single forecast of where your heart is headed — a living risk trajectory that updates in real time. Pair that with a new generation of drugs that crush the most dangerous cholesterol particles, cool inflammation, and protect the heart independent of weight — and primary prevention becomes something we've never had before: precise. Put all five together and something historic becomes possible: We can identify the person who is going to have a heart attack in 2045 — today. And we can rewrite that ending. Here's why this matters more than almost anything else in medicine. Of the great age-related killers — cancer, dementia, heart disease — heart disease is the most preventable. We already have the lifestyle levers. We already have medications that work. Statins alone cut the risk of a major cardiac event by roughly 20–25% for each substantial drop in LDL, and we've held that power for years. What we lacked was knowing exactly who to protect, and when to begin. Now we're being handed the map. Picture it: a routine checkup — or even an eye exam — quietly generating a risk profile that says this person needs us now, not in thirty years. That is not science fiction. Every single piece already exists and is maturing fast. I became a cardiologist to save lives. And I'm realizing the most powerful version of that was never the dramatic rescue at midnight. It's the heart attack that never happens. The room you never end up in. The ordinary Tuesday, twenty years from now, that you simply get to keep — never knowing how close you came to losing it. The tools are finally here. Our only job now is the courage to use them early — to stop waiting for the body to break before we're willing to care for it. The future of the heart isn't a better rescue. It's a life that never needed rescuing.

I'm a cardiologist. Curcumin may be one of the most legitimately promising anti-inflammatory compounds available — and the exact form that works best is the one with documented cases of liver injury. That tension is the whole story, and almost nobody tells it honestly. Let me give you both halves. First, why the form matters more than the compound. Standard turmeric and cheap curcumin are almost pharmacologically useless. Absorption is dismal, the liver metabolizes it within minutes, and blood levels barely register. Most people taking turmeric capsules are essentially taking an expensive yellow placebo. Phytosomal curcumin — curcumin bound to phospholipids, the best-studied being Meriva — changes that completely. A randomized crossover trial in the Journal of Natural Products found 29-fold higher total absorption compared to standard curcuminoids. That single fact explains why decades of curcumin research looked underwhelming. We were testing a molecule that never reached the bloodstream. What the absorbed form actually does. It works upstream, at the genetic level, by downregulating NF-κB — the master switch controlling inflammatory gene expression. Downstream of that: reduced TNF-alpha, IL-6, and COX-2. TNF-alpha is the one I find most interesting. It's a central driver of "inflammaging" — the chronic low-grade inflammation that accelerates biological aging. It's the same target as the TNF-inhibitor drugs used in rheumatoid arthritis, which observational data has linked to substantially lower Alzheimer's risk. Lowering TNF-alpha through a supplement is not the same as a biologic drug. But the pathway is real, and it's the right pathway. The human evidence that impressed me most. This isn't cell culture. In a multicenter randomized trial, 52 biopsy-proven MASH patients received Meriva 2g/day or placebo for 72 weeks. Biopsy-proven. Seventy-two weeks. That's a serious trial design for a supplement. Additional randomized trials in NAFLD have shown reductions in ALT, AST, cholesterol, triglycerides, waist circumference, and liver volume. As a cardiologist, that matters — fatty liver and cardiovascular disease share the same metabolic root, and ALT is one of the most underread markers on a standard panel. Now the part the enthusiasts leave out. The NIH's LiverTox database documents several dozen cases of clinically apparent acute liver injury attributed to turmeric products — and it specifically implicates the high-bioavailability forms. There was an outbreak of acute hepatitis with jaundice in Italy traced to enhanced-absorption curcumin. Sit with the irony: the reason these formulations work is the same reason they can hurt you. You made a poorly absorbed compound highly absorbed. You did not merely increase the benefit. You increased the dose the liver actually sees. A genetic susceptibility has been identified — an HLA variant that appears to predispose certain people. Most will never have a problem. Some will. And a note on piperine. Many products add black pepper extract to boost absorption. It works — by inhibiting the liver enzymes that clear the compound. That same mechanism affects how your liver clears your other medications. If you take anything metabolized hepatically, this matters. Meriva achieves its absorption through phospholipids rather than enzyme blockade, which is one argument in its favor. So where do I land? This is one of the few natural compounds with genuine randomized human data hitting a mechanism that matters. I take it seriously. But treat it like a drug, because pharmacologically that is what an enhanced-absorption formulation is. Get a baseline ALT and AST before starting, and recheck at 8-12 weeks. That single step converts an unmonitored risk into a managed one, and virtually nobody does it. Skip it entirely if you have existing liver disease, gallbladder disease, or bile duct obstruction. Curcumin stimulates gallbladder contraction and can worsen biliary colic. Be cautious if you're on blood thinners — it has antiplatelet effects. And stop immediately for dark urine, yellowing eyes, right upper quadrant pain, or unexplained fatigue. The lesson underneath this is bigger than curcumin. We've been trained to believe "natural" means "safe," so we skip the monitoring we'd never skip with a prescription. But a supplement engineered for 29-fold absorption isn't a spice anymore. It's pharmacology in a capsule with no oversight. The compound may genuinely help you. Just check your liver while it does.

I’m a centrist democrat but the uncomfortable truth I have realized this election cycle is that while democratic socialist candidates are willing to give the fight even if they are wrong, many centrist candidates are quite toothless. What does a man have to do to see a centrist candidate say that Trump is the personification of blatant corruption, that the DSA is anti-America, and that they will fight to the end to keep them out of power while making American lives easier? Yet all I see are centrists being scared of attracting controversy in the middle of a political campaign. 🫠

I'm a cardiologist. A review published this morning just took a sledgehammer to the protein-maxxing era. And the most important detail isn't in the headline — it's buried in the human data. Lamming's lab at Wisconsin reviewed over 350 studies on protein restriction and aging, published today in Cell Press Blue. As @EricTopol put it, they define — for the first time — the hallmarks of protein restriction: Improved metabolic health. Induction of nutrient-sensing pathways. Decreased senescence. Improved mitochondrial function. An altered epigenome. And the promotion of healthy aging. Six hallmarks. From eating less protein, while still meeting your needs. 𝗧𝗵𝗲 𝗻𝘂𝗺𝗯𝗲𝗿𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗺𝗼𝗱𝗲𝗹𝘀 Flies: up to 122% longer life. Rodents: 10-50%+ gains. Methionine restriction alone: 7-42% lifespan extension. Cutting isoleucine and valine: 23-65% in various setups — with less frailty and less cancer. 𝗧𝗵𝗲 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝘀𝗵𝗼𝘂𝗹𝗱 𝘀𝗼𝘂𝗻𝗱 𝗳𝗮𝗺𝗶𝗹𝗶𝗮𝗿 Excess protein — especially leucine, isoleucine, valine, and methionine — keeps mTOR switched on. mTOR is the growth accelerator. Keep it humming and autophagy shuts down, cells stop cleaning house, and senescent "zombie" cells accumulate. Restrict protein and it reverses. mTOR quiets. GCN2 activates autophagy. And FGF21 surges — driving fat burning, insulin sensitivity, and lower inflammation. This is the exact pathway rapamycin targets. The exact pathway fasting targets. We've been chasing it with drugs while telling everyone to eat more of the thing that blocks it. 𝗧𝗵𝗲 𝗵𝘂𝗺𝗮𝗻 𝗱𝗮𝘁𝗮 — 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗳𝗶𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗮𝘁 𝗰𝗵𝗮𝗻𝗴𝗲𝘀 𝗲𝘃𝗲𝗿𝘆𝘁𝗵𝗶𝗻𝗴 Levine's landmark Cell Metabolism study followed adults for 18 years. Those aged 50-65 with high protein intake had a 75% increase in overall mortality and a four-fold increase in cancer death. But here's the line nobody quotes: those associations were abolished or attenuated when the protein was plant-derived. Same amount of protein. Different source. Different outcome. And the age flip matters enormously: over 65, high protein was associated with reduced mortality. Your protein needs change with age — in the opposite direction from what the influencers say. 𝗧𝗵𝗲 𝗵𝗼𝗻𝗲𝘀𝘁 𝗰𝗮𝘃𝗲𝗮𝘁𝘀 Topol's own caution is right: this review rests largely on model organisms. So does most of the healthspan literature, including rapamycin — but "true in mice" isn't "true in humans," and I won't pretend otherwise. And Lamming himself gave the nuance that saves this from being clickbait: athletes consume enormous protein without developing metabolic disease. He suspects exercise protects them — the protein goes into building muscle instead of idling in growth pathways. So the finding isn't "protein is bad." It's that protein without exercise may be the problem. A sedentary person drinking protein shakes, eating protein cereal and protein water is chronically flooring a growth pathway with nothing demanding growth. 𝗪𝗵𝗲𝗿𝗲 𝗜 𝗹𝗮𝗻𝗱, 𝗮𝘀 𝗮 𝗰𝗮𝗿𝗱𝗶𝗼𝗹𝗼𝗴𝗶𝘀𝘁 If you're sedentary and eating 1.5-2g/kg because an influencer told you to — the data doesn't support it, and it may be working against you. If you lift hard 3-4x a week, that protein has somewhere to go. Different equation. And if you're over 70 or frail — do not cut your protein. Sarcopenia will kill you faster than mTOR will. Older adults and pregnant women need more, and the authors say so explicitly. I still believe the Mediterranean diet is the best diet on earth, and this review is the mechanistic explanation of why. It delivers moderate protein — mostly plants, legumes, nuts, fish. Lower methionine density. Olive oil, fiber, polyphenols. It hits every lever this paper describes without a single scoop of powder. Lamming's own lab tested it: a low-protein diet modeling the traditional Mediterranean and Okinawan patterns, head-to-head against Western and ketogenic diets. Western and keto increased fat mass and frailty. The Mediterranean-style diet reduced both and improved cardiometabolic markers. Traditional Okinawa ran about 9% of calories from protein. The blue zones didn't drink protein shakes. They ate beans, and they moved every single day.

I'm a cardiologist. Four surgeries that millions of people have undergone work no better than fake surgery — where the surgeon cuts the skin, pretends to operate, sews you back up, and does nothing else. The patients who got the fake operation improved just as much as the ones who got the real one. This isn't fringe skepticism. It's from rigorous, blinded, randomized trials in the New England Journal of Medicine and the BMJ. And it reveals something profound about the human body — and about how much of medicine is ritual. Here's what the sham-controlled trials actually found: 𝗞𝗻𝗲𝗲 𝗮𝗿𝘁𝗵𝗿𝗼𝘀𝗰𝗼𝗽𝘆 𝗳𝗼𝗿 𝗮𝗿𝘁𝗵𝗿𝗶𝘁𝗶𝘀. A landmark 2002 trial randomized patients to real "cleanout" surgery or fake surgery — skin incisions only, no actual procedure. Two years later, pain and walking ability were identical across groups. This was one of the most common orthopedic operations in America — hundreds of thousands a year, over a billion dollars. Guidelines now advise against it. The improvement was real. The scraping had nothing to do with it. 𝗠𝗲𝗻𝗶𝘀𝗰𝘂𝘀 𝘀𝘂𝗿𝗴𝗲𝗿𝘆 𝗳𝗼𝗿 𝗱𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝘁𝗲𝗮𝗿𝘀. The 2013 Finnish FIDELITY trial compared real meniscus trimming to sham surgery. One year later, the results were the same. This was historically one of the most performed operations on earth — around 700,000 a year in the US. And later data suggests the real surgery may actually accelerate arthritis in some patients. 𝗦𝗵𝗼𝘂𝗹𝗱𝗲𝗿 𝗱𝗲𝗰𝗼𝗺𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝗳𝗼𝗿 𝗶𝗺𝗽𝗶𝗻𝗴𝗲𝗺𝗲𝗻𝘁. The 10-year follow-up of the FIMPACT trial, published in the BMJ in 2025, found real surgery beat placebo surgery by about 1.5 points on a 100-point pain scale. You need around 15 points to even notice a difference. It was also no better than simple exercise therapy. 𝗩𝗲𝗿𝘁𝗲𝗯𝗿𝗼𝗽𝗹𝗮𝘀𝘁𝘆 𝗳𝗼𝗿 𝘀𝗽𝗶𝗻𝗮𝗹 𝗳𝗿𝗮𝗰𝘁𝘂𝗿𝗲𝘀. Two 2009 NEJM trials compared injecting cement into fractured vertebrae to a fake procedure — same needle, same pressure, even the smell of cement, but no injection. No meaningful difference. Both groups improved fast. Why does this happen? Because for subjective outcomes like pain, the ritual of surgery is one of the most powerful placebos in all of medicine. The anesthesia. The operating room. The care. The deep psychological closure of believing something decisive was done to fix you. That effect is often larger than any pill — and when you control for it, several high-volume operations simply collapse. Now the honest other half, because I won't overstate this. Not every surgery is placebo. Many are genuine, life-saving mechanical fixes. Even in cardiology, stents for stable angina looked no better than sham in the first ORBITA trial — but when the follow-up study controlled it more precisely, the stent clearly reduced symptoms. Real fixes can and do beat placebo. These four just didn't, for these conditions. And these trials are rare, because sham surgery is ethically and logistically hard to run. Which means there are almost certainly other common procedures we've simply never tested this way. So here is what I want you to do if you're ever offered surgery for chronic pain. Ask one question: "What did the sham-controlled trial show?" For many joint and back pain conditions, physical therapy, exercise, weight loss, and time match or beat the operation — without the infection risk, the anesthesia risk, the blood clots, the cost, and the recovery. Surgery is sometimes exactly what you need. But sometimes the most powerful treatment in the room is simply the belief that treatment has occurred. Your body has more healing power than the system profits from admitting.

I'm a cardiologist. For the first time in modern American history, more people get high every day than drink every day. 17.7 million Americans now use cannabis daily or near-daily — versus 14.7 million daily drinkers. Thirty years ago it was the reverse, ten to one the other way. A Carnegie Mellon analysis of 40 years of federal data confirmed the flip. We are running a civilization-scale experiment in real time. And I don't think most people have looked honestly at the science, because it's become culturally impossible to criticize weed without sounding like a narc. So let me be the doctor who says it plainly. This is not the mild plant of the 1970s. Then, cannabis was 1-3% THC. Today's products run 15-25%, and concentrates — dabs, vapes, wax — hit 70-90%+. When people say "it's natural, it's harmless," they're defending a product that no longer exists. We didn't legalize the old plant. We industrialized a far more potent one. Here's what the strongest evidence actually shows, and I'll keep it to what's real: The developing brain is the real casualty. The Dunedin study — following 1,000 people for decades — found that persistent cannabis use starting in adolescence was associated with a lasting decline of several IQ points that didn't fully recover after quitting. The prefrontal cortex, the seat of judgment and impulse control, is still wiring until about 25. Heavy THC during that window appears to leave a mark. The psychosis link is not fringe anymore. Daily use of high-potency cannabis is associated with roughly a 3-5x higher risk of psychosis. A major European study found high-potency products alone accounted for a substantial share of new psychosis cases in some cities. This is one of the most replicated findings in the field, and it's the one people most want to ignore. And cannabis use disorder is real — up to 3 in 10 users develop some degree of dependence, higher when use starts young. "You can't get addicted to weed" is simply false. Now the honest caveats, because I won't overstate to make a point. Correlation isn't proof — some of the psychosis link may run both directions, with vulnerable brains drawn to heavier use. Cannabis has genuine medical uses: chemo nausea, certain seizure disorders, some chronic pain. A moderate adult using occasionally is in a very different category than a 16-year-old dabbing daily. And alcohol and tobacco still cause vastly more total death. This isn't "weed is worse than everything." It's "weed is not harmless, and the dose has changed." Here's my concern as a physician watching the culture. We swung from "reefer madness" hysteria straight to "it's basically a vitamin," and skipped the honest middle entirely. The truth is that a high-potency daily habit — especially in a young brain — quietly lowers the ceiling. Flattens drive. Blurs the sharpness a person needs to build a life. If you're an adult who enjoys it occasionally, that's your call. But if it's daily, if it's high-THC, and especially if it's anyone under 25 — the science is asking you to reconsider. Go outside. Sweat. Build something. Sleep hard. Stay sharp. The clearest mind in the room is about to become the rarest one. Make sure it's yours.

I'm a cardiologist. A new study found that one specific form of magnesium made adults' brains perform as if they were 7.5 years younger — in just 6 weeks. The catch, and the caveats, matter. Here's the honest version. The study, published in Frontiers in Nutrition, randomized 100 healthy adults with poor sleep to either 2g of magnesium L-threonate (Magtein) daily or placebo, double-blind, for 6 weeks. The results in the magnesium group: overall cognition improved more than placebo. Working memory showed the biggest gains. Reaction time and hand-eye coordination improved 6.3%. And on the physiology side — the part that interests me as a cardiologist — resting heart rate during sleep dropped and heart rate variability rose, both signs of a healthier, calmer nervous system. The "7.5 years younger" headline comes from translating the cognitive score difference into age-equivalent norms. It's a real, intuitive way to frame the gain — but let me be clear about what it is and isn't. Why this particular form matters: most magnesium — oxide, citrate, even glycinate — doesn't cross into the brain efficiently. Magnesium L-threonate was engineered specifically to raise brain magnesium levels, using the threonate carrier to get across the blood-brain barrier. Magnesium is a cofactor in over 300 enzyme reactions, and in the brain it supports synaptic plasticity, neuronal energy, and the electrical stability of your neurons. Most people are quietly low in it. Now the caveats, because this is where supplement hype lies to you: The study was funded by the company that holds the Magtein patent, which is common in supplement research but raises real bias risk until independent labs replicate it. It was short — 6 weeks. The participants were young and healthy and already scoring at or above age norms. There was no benefit on fluid intelligence. And "7.5 years younger" is a modeled score translation, not a reversal of brain aging on any biological scan. So: promising, not revolutionary. Here's my practical read as a physician who already recommends magnesium daily. If you're deficient — and most people are — fixing your magnesium status is one of the highest-value, lowest-risk things you can do for sleep, blood pressure, rhythm, and mood. I typically recommend magnesium glycinate at night for sleep and calm. This study makes a reasonable case that if brain and cognition are your specific target, the L-threonate form may deliver something the others can't — better brain penetration. Some people stack a small dose of L-threonate for cognition with glycinate for sleep. It's not magic. It's better delivery of an essential mineral you're probably not getting enough of. Get your magnesium status right first. Then decide, with your doctor, whether the brain-targeted form earns a place in your stack. The best nootropic is rarely exotic. Often it's just correcting the deficiency you already had.